Earlier Patient Access – the UK Early Access to Medicines Scheme (EAMS)

Access to hepatitis C medicines

Hepatitis C is a global epidemic. Worldwide, 185 million people are estimated to be infected, most of whom live in low- and middle-income countries. Recent advances in the development of antiviral drugs have produced therapies that are more effective, safer and better tolerated than existing treatments for the disease. These therapies present an opportunity to curb the epidemic, provided that t...

pharmaceutical strategic purchasing: a key to improve access to medicines

pharmaceuticals are often considered as the most significant cost driver of health care expenditures and at the same time have a major impact on patients’ curative processes and outcomes. other pieces of evidence emphasize that drugs are the input for the production of good health. they are considered as the most important and expensive element in the healthy supply chain and are more associate...

Patient Safety and Healthcare Quality: The Case for Language Access

This paper aims to provide a description of the need for Culturally and Linguistically Appropriate Services (CLAS) for Limited English Proficient (LEP) patients, an identification of how the lack of CLAS for LEP patients can compromise patient safety and healthcare quality, and discuss barriers to the provision of CLAS.

Access to medicines - overcoming the barriers.

Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient.

5 Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430–1442. 6 Migliori GB, Sotgiu G. Treatment of tuberculosis: have we turned the corner? Lancet 2012; 380: 955–957. 7 De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem...